Utilizing a ‘network’ analysis of proteins, Visterra’s innovative technology platform enables a more in depth structural understanding of proteins to identify unique target epitopes and guide the design of novel drugs that specifically target these epitopes to effectively combat disease.

Visterra’s primary focus is the application of its technology to infectious disease, and its most advanced product in development is a broad spectrum antibody for influenza. Visterra was founded by MIT Professor Ram Sasisekharan and Polaris partner Alan Crane.

Contact Info

One Kendall Square, Suite B3301, Cambridge, MA, 02139
Tel: 617-498-1070

Polaris Lead

Alan Crane / Kevin Bitterman

Social Media